Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 8Primary Myelofibrosis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Thrombocythemia, Essential 4Recurrence 4Polycythemia Vera 4Multiple Myeloma 4Leukemia 4Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Graft vs Host Disease 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, T-Cell, Peripheral 2Lymphoma 2Leukemia, Prolymphocytic, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Large Granular Lymphocytic 2Hematologic Neoplasms 2Triple Negative Breast Neoplasms 1Targeted Therapy 1Prostatic Neoplasms 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Cyclophosphamide 13pembrolizumab 8Brentuximab Vedotin 8fludarabine 7Nivolumab 7Whole-Body Irradiation 6Specimen Handling 6Mycophenolic Acid 6Gemcitabine 6Etoposide 6Doxorubicin 6Dacarbazine 6fludarabine phosphate 5Vinblastine 5Melphalan 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5Dexamethasone 5Stem Cell Transplantation 4Cytarabine 4Vinorelbine 3Tacrolimus 3Magnetic Resonance Spectroscopy 3Cyclosporine 3Carmustine 3Blood Specimen Collection 3thymoglobulin 2polatuzumab vedotin 2pegylated granulocyte colony-stimulating factor 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Hodgkin Disease × ruxolitinib × Clear all
NCT03681561 2026-03-09

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Big Ten Cancer Research Consortium

Phase 1/2 Recruiting
54 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡